(Q37350395)

19 August 2017

1 reference

title

Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology (English)

1 reference

19 August 2017

0 references

Lennox-Gastaut sindrome

1 reference

Jacqueline French

2

0 references

Emilio Perucca

11

object named as

Emilio Perucca

1 reference

19 August 2017

8

Renzo Guerrini

1 reference

19 August 2017

Alexis Arzimanoglou

1

1 reference

19 August 2017

Warren T Blume

3

1 reference

19 August 2017

J Helen Cross

4

1 reference

19 August 2017

Jan-Peter Ernst

5

1 reference

19 August 2017

Martha Feucht

6

1 reference

19 August 2017

Pierre Genton

7

1 reference

19 August 2017

Gerhard Kluger

9

1 reference

19 August 2017

John M Pellock

10

1 reference

19 August 2017

James W Wheless

12

1 reference

19 August 2017

language of work or name

1 reference

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

82-93

1 reference

Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as "petit mal variant") or Lennox syndrome

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

An electro-clinical study of generalized epileptic seizures of tonic expression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Atypical benign partial epilepsy of childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Generalized sharp and slow wave complexes. Associated clinical features and long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Sodium valproate: monotherapy and polytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

A risk-benefit assessment of therapies for Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Lennox-Gastaut syndrome (childhood epileptic encephalopathy).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Open study of clobazam in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Treatment of infantile spasms and Lennox-Gastaut syndrome with clonazepam (Rivotril)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Levetiracetam in the treatment of Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

1 reference

7 January 2021

Zonisamide in the management of epilepsy--Japanese experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Zonisamide for the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

ACTH and prednisone in childhood seizure disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Antiepileptic drugs as a cause of worsening seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Treatment of pediatric epilepsy: expert opinion, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Defining the problem: psychiatric and behavioral comorbidity in children and adolescents with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Effects of antiepileptic medications on psychiatric and behavioral comorbidities in children and adolescents with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Optimizing therapy of seizures in children and adolescents with ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Optimizing therapy of seizures in children and adolescents with developmental disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Antiepileptic drug treatment in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Therapeutic drug monitoring of old and newer anti-epileptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Is there a role for therapeutic drug monitoring of new anticonvulsants?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Effects of early and late transection of the corpus callosum in children. A study of tactile and tactuomotor transfer and integration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Nonpharmacologic treatment of the catastrophic epilepsies of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Vagus nerve stimulation treatment for Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970292-8

7 January 2021

10.1016/S1474-4422(08)70292-8

Identifiers

DOI

1 reference

19 August 2017

1 reference